

Breast Cancer

## A study in T-DM1 for use in patients with breast cancer after chemotherapy

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

**Trial Status**  
Completed

**Trial Runs In**  
0 Countries

**Trial Identifier**  
NCT01196052

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive breast cancer. Patients received T-DM1 3.6 mg/kg intravenously on Day 1 of each 3-week cycle, for up to 17 cycles.

**F. Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

**NCT01196052**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
18 years and older

**Healthy Volunteers**  
No